{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-014653","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2026-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.792444+00:00","generated_at":"2026-05-15T07:59:16.961665+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"bioAffinity Q1 2026 CyPath Lung unit sales surge 146% YoY, beat projections","bullets":["Q1 2026 CyPath Lung unit sales up 146% YoY, exceeding internal projections on accelerating physician adoption.","Full-year 2025 CyPath Lung revenue rose 87% YoY, units sold up 99% vs 2024.","Addressable U.S. market estimated at $3.58 billion; capturing 10% would represent $358M in sales.","Company advancing large-scale clinical study and R&D pipeline for asthma/COPD diagnostics."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-014653","json":"https://secwatch.observer/filing/0001493152-26-014653.json","markdown":"https://secwatch.observer/filing/0001493152-26-014653.md","text":"https://secwatch.observer/filing/0001493152-26-014653.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226014653/0001493152-26-014653-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226014653/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:59:16.961665+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}